Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

4/22/25 4:04:59 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ELUT alert in real time by email

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia's Chief Scientific Officer, will participate in Chardan's Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.

Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – Virtual

Format: Fireside Chat

Date and Time: Tuesday, April 29, 2025, 11:00 a.m. ET (8:00 a.m. PT)

Webcast: Click Here

A live and archived webcast of the fireside chat will be available in the "Investors" section of the Elutia website at http://investors.elutia.com/.

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:

Matt Steinberg

FINN Partners

[email protected]

This press release was published by a CLEAR® Verified individual.

Get the next $ELUT alert in real time by email

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

Chat with this insight

Recent Analyst Ratings for
$ELUT

$ELUT
SEC Filings

Elutia Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

SEC Form SCHEDULE 13G filed by Elutia Inc.

$ELUT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

$ELUT
Press Releases

Fastest customizable press release news feed in the world

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

Chat with this insight

Recent Analyst Ratings for $ELUT

$ELUT SEC Filings

Elutia Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

SEC Form SCHEDULE 13G filed by Elutia Inc.

$ELUT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

$ELUT Press Releases

Fastest customizable press release news feed in the world

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

Recent Analyst Ratings for
$ELUT

$ELUT
SEC Filings

$ELUT
Insider Purchases

$ELUT
Press Releases